SP 160412

Drug Profile

SP 160412

Alternative Names: SP160412

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sephoris Pharmaceuticals
  • Class Antiallergics; Antihistamines; Nonsteroidal anti-inflammatories; Phenylpropionates; Sedating antihistamines
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Photodamage

Most Recent Events

  • 15 Nov 2017 Sephoris Pharmaceuticals plans a phase II trial in Photodamage in USA in November 2017 (NCT03332524)
  • 06 Nov 2017 Preclinical trials in Photodamage in USA (PO) (NCT03332524)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top